Abstract
Batches of frusemide tablets were produced using Explotab, polyplasdone XL, Amberlite IRP88, maize atarch, and Elcesan P100 as disintegrants. Bioavailability atudies were carried out on a double blind basis.
The bioavailability differences between formulations was shown to be significant. Explotab rendered the fruseulide far more bioevailable than the other four disintegrants.